SOPA Image | Lightrocket | Getty Image
Merck On Tuesday, we issued a profit guidance for 2025 years. As a result, the expectation of Wall Street was insufficient.
Merck’s shares decreased by 11 % on Tuesday.
Pharmaceutical Giant anticipates sales from $ 64.1 billion to $ 65.6 billion, lower than $ 673.1 billion, which was expected by LSEG’s investigated analysts. In the release, the company said that the sales range reflected the decision to suspend the shipment of Gardasil to China, which has been held at least in mid -2025 since February.
Gardasil is a vaccine to prevent HPV cancer. The most common sexually transmitted diseases in the United States have become unstable in the past year due to the problem of selling huge hit shots in China. 。
At Merck’s earning guidance low -end, there is no further shipment in China, and high -end sales are less than $ 1 billion.
Merck’s CEO, Robert Davis, said in a call for revenue, saying that the stock of Gardasil in China was “rising beyond normal levels”, and the demand for shots has softened consumer spending. He said that it has not recovered to the expected level. Delivery of delivery will enable “reduction of excessive stock” and supports the financial status of China, a commercialization partner in China.
Davis also hopes that the delivery of delivery will help Gardasil return to “Dynamic in the Normal Market”, and allows the fundamental demand of shots to absorb Zhifei’s inventory. He said he wanted that. He pointed out how fast Merck could lower the inventory level.
Merck said that it had withdrawn Gardasil’s annual sales target of 11 billion dollars in consideration of the uncertain timing of China’s economic recovery, said on Tuesday. However, she said that the company still believes that there is still a “way” to the profit goal.
The sale of shots is probably important for Merck’s efforts to offset the loss from Keytruda, the top of the cancer therapy, which loses exclusiveness in 2028. A shot.
“We believe that China is a major long -term opportunity for Gardasil, considering many women, and the men who are now recent approval have not yet been vaccinated. Davis said.
Merck expects a profitable profit from $ 8.88 per share to $ 9.03. This is generally in line with what analysts expected. The outlook reflects the price of about 9 cents per share related to Merck’s license agreement with Ranova, a private drug maker.
With the sale of Keytruda, other tumor medicine, and the company’s recently launched cardiovascular treatment, Merck lost his expectations for the fourth quarter of 2024.
Based on the LSEG analyst survey, Merck reported in the fourth quarter compared to what Wall Street was expecting.
Profit per share: $ 1.72 adjusted to $ 1.62: $ 156.2 billion vs. 154.9 billion
The company recorded $ 3.74 billion in the quarter, $ 1.48 per share. This is compared to $ 1.23 billion compared to the previous year, that is, 48 cents per share.
Merck won $ 1.72 per share in the fourth quarter, except for acquisition costs and reorganization costs. Both adjusted revenue and non -adjusted revenues reflect 23 cents per share related to Merck’s recent license agreements, including experimental obese agreements from drug manufacturers in China. Masu.
Merck increased by $ 156.2 billion in quarterly, increased by 7 % from the same period a year ago.
Pharmaceutical department
Merck’s pharmaceutical monitoring, which develops a wide range of drugs, has booked $ 14.04 billion in the fourth quarter. This has increased by 7 % from the same period a year ago.
Keytruda recorded $ 7.84 billion in a quarter and increased 19 % from the previous year. According to StreetAccount, analysts anticipated $ 7.63 billion.
This increase was promoted by higher Keytruda intake of early cancer and strong demand for drugs for metastases that spread to other parts of the body.
According to SteetAccount’s estimation, Gardasil decreased by 17 % from the fourth quarter of 2023, down 17 % from the fourth quarter of 2023.
JANUVIA, a Type 2 diabetes treatment in Merck, also decreased by $ 487 million in a quarter, decreasing by 38 % from the same period of the previous year. The company stated that the decline was mainly due to US prices, Chinese supply constraints, and continuous competition with inexpensive generic drugs in the international market.
According to StreetAccount, this was less than $ 500 million for analyst estimates during that period.
Januvia is one of the 10 drugs subject to media -care drug price negotiations, and is based on an inflation -reduction method aimed at making more affordable drugs for elderly Americans. is. A new negotiating price for the first round of drugs will be enforced in 2026.
The Merck’s Animal Health Bureau, which develops dogs, cats, and cow vaccines and drugs, has recorded nearly $ 1.4 billion sales, 9 % increased from the same period a year ago. The company stated that the price of the entire portfolio was high as the price increased.
